Axogen, Inc. (LON:0HKD)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 566.49M |
| Revenue (ttm) | 148.37M |
| Net Income (ttm) | -3.40M |
| Shares Out | n/a |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | 47.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27 |
| Average Volume | 1,518 |
| Open | 16.31 |
| Previous Close | 16.68 |
| Day's Range | 16.31 - 16.31 |
| 52-Week Range | 9.29 - 20.97 |
| Beta | 0.76 |
| RSI | 63.90 |
| Earnings Date | Nov 7, 2025 |
About Axogen
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc... [Read more]
Financial Performance
In 2024, Axogen's revenue was $187.34 million, an increase of 17.81% compared to the previous year's $159.01 million. Losses were -$9.96 million, -54.12% less than in 2023.
Financial numbers in USD Financial StatementsNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to con...
Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted
Shares of Axogen plunged Monday after the FDA delayed the expected approval date for the company's nerve graft product.
Axogen falls 16% after FDA delays Avance Nerve Graft decision to December
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
ALACHUA, Fla. and TAMPA, Fla.
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined
Axogen (AXGN) Q2 Revenue Jumps 18%
Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript
Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen gains on report of takeover interest
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript
Axogen, Inc. (NASDAQ:AXGN) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsMichael Dale - Chairman & Chief Executive...
Axogen names Lindsey Hartley as finance chief
Axogen, Inc. Reports 2025 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today ...
Axogen and ADMA Biologics expect low to zero impact from recent tariffs
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript
Axogen Inc (AXGN) Q4 Earnings: EPS of $0.01 Beats Estimate, Revenue of $49.4M Surpasses Forecast
Axogen Inc (AXGN) Q4 Earnings: EPS of $0.01 Beats Estimate, Revenue of $49.4M Surpasses Forecast
AxoGen Non-GAAP EPS of $0.07 beats by $0.03, revenue of $49.4M in-line
Axogen, Inc. To Host Analyst & Investor Day on March 4th
ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, w...
Earnings Scheduled For February 25, 2025
Companies Reporting Before The Bell • Super Group (SGHC) (NYSE: SGHC) is estimated to report earnings for its fourth quarter. • Carter's (NYSE: CRI) is expected to report quarterly earnings at $1.90...
AxoGen Q4 2024 Earnings Preview
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...